Semaglutide in Nondiabetic CKD and SC0062 for IgAN

By Hiddo Heerspink, PhD, Joel M. Topf, MD, FACP - Last Updated: November 7, 2024

ASN Kidney Week 2024 was an exciting time for Hiddo Heerspink, PhD. He won the Donald W. Seldin Young Investigator Award and gave the Seldin address in addition to co-authoring several Kidney Week abstracts. Dr. Heerspink was an author of a late-breaking oral presentation on SC0062, a new selective endothelin receptor type A antagonist in IgAN, and a high-impact abstract on effects of semaglutide on kidney parameters with obesity and nondiabetic CKD. He spoke with Joel Topf, MD, about the findings and his award win.

Advertisement

Advertisement